Skip to content

PHARMACYTE BIOTECH, INC.: 10-Q filed 2012-03-21

What PHARMACYTE BIOTECH, INC. reported in its quarterly report filed 2012-03-21 (fiscal Q3 2012): 30 published measures, 80 facts as tagged in accession 0001262463-12-000081.

This filing

Form
10-Q (quarterly report)
Filed
2012-03-21
Fiscal period
fiscal Q3 2012
Accession
0001262463-12-000081 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All PHARMACYTE BIOTECH, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-01-311,863,494USD
At 2011-04-301,240,187USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-01-313,531,283USD
At 2011-04-303,389,480USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-01-31-2,247,789USD
At 2011-04-30-2,729,293USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-01-3139,077USD
At 2011-04-3057,201USD
At 2011-01-313,614USD
At 2010-04-30716USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2011-11-01 to 2012-01-31-271,777USD92
2011-05-01 to 2012-01-31-1,394,949USD276
2010-11-01 to 2011-01-31-124,101USD92
2010-05-01 to 2011-01-31-304,180USD276

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2011-05-01 to 2012-01-31-207,334USD276
2010-05-01 to 2011-01-31-83,361USD276

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2011-11-01 to 2012-01-3120,271USD92
2011-05-01 to 2012-01-3159,877USD276
2010-11-01 to 2011-01-3132,022USD92
2010-05-01 to 2011-01-3174,851USD276

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2011-05-01 to 2012-01-31869,210USD276
2010-05-01 to 2011-01-3186,259USD276

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2011-05-01 to 2012-01-31-680,000USD276
2010-05-01 to 2011-01-310USD276

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-01-31-39,343,642USD
At 2011-04-30-37,948,693USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2011-11-01 to 2012-01-31373,337,581shares92
2011-05-01 to 2012-01-31371,867,725shares276
2010-11-01 to 2011-01-31348,387,581shares92
2010-05-01 to 2011-01-31348,387,581shares276

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2011-11-01 to 2012-01-310USD/shares92
2011-05-01 to 2012-01-31-0.01USD/shares276
2010-11-01 to 2011-01-310USD/shares92
2010-05-01 to 2011-01-310USD/shares276

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-01-3130,587USD
At 2011-04-3054,440USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2011-05-01 to 2012-01-311,252,453USD276
2010-05-01 to 2011-01-310USD276

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-01-31751,907USD
At 2011-04-30104,747USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2011-11-01 to 2012-01-31-35,756USD92
2011-05-01 to 2012-01-31-102,597USD276
2010-11-01 to 2011-01-31-55,327USD92
2010-05-01 to 2011-01-31-136,893USD276

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-01-313,283,349USD
At 2011-04-303,389,480USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-01-31572,259USD
At 2011-04-30705,763USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2011-11-01 to 2012-01-31428,041USD92
2011-05-01 to 2012-01-311,502,267USD276
2010-11-01 to 2011-01-3178,816USD92
2010-05-01 to 2011-01-31210,377USD276

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2012-01-312,307USD
At 2011-04-3018,706USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2011-11-01 to 2012-01-3118,060USD92
2011-05-01 to 2012-01-3135,955USD276
2010-11-01 to 2011-01-3110,042USD92
2010-05-01 to 2011-01-3143,090USD276

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2011-11-01 to 2012-01-312,211USD92
2011-05-01 to 2012-01-3123,922USD276
2010-11-01 to 2011-01-3121,980USD92
2010-05-01 to 2011-01-3131,761USD276

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-01-3135,460,200USD
At 2011-04-3034,415,655USD

Long-term debt

Long-term borrowings under this concept, which can include the current portion depending on presentation. It is not total liabilities and may exclude leases and other obligations.

PeriodValueUnitDays
At 2012-01-31247,934USD
At 2011-04-300USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-01-31356,254USD
At 2011-04-30274,144USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2011-11-01 to 2012-01-3131,565USD92
2011-05-01 to 2012-01-31289,147USD276
2010-11-01 to 2011-01-3177,818USD92
2010-05-01 to 2011-01-31202,372USD276

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2011-05-01 to 2012-01-31621,000USD276
2010-05-01 to 2011-01-310USD276

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2011-05-01 to 2012-01-31-17,263USD276
2010-05-01 to 2011-01-31-19,907USD276

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2011-05-01 to 2012-01-3116,399USD276
2010-05-01 to 2011-01-311,645USD276

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2011-05-01 to 2012-01-31-32,044USD276
2010-05-01 to 2011-01-3173,892USD276

Inspect the source

Entity
PHARMACYTE BIOTECH, INC. / CIK 0001157075
Captured
2026-09-20T07:42:36.237Z
SEC response SHA-256
8f9ad1662a11f3cb167c6975b558c6cce5e582ddebd7699a946a7cffe2a40413

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001157075.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))